BioCryst Pharmaceuticals Inc (BCRX)
5.07
-0.08
(-1.55%)
USD |
NASDAQ |
Mar 28, 16:00
5.09
+0.02
(+0.39%)
After-Hours: 20:00
BioCryst Pharmaceuticals Cash from Financing (TTM): 32.48M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 32.48M |
September 30, 2023 | 39.86M |
June 30, 2023 | 114.96M |
March 31, 2023 | 85.75M |
December 31, 2022 | 88.03M |
September 30, 2022 | 431.25M |
June 30, 2022 | 359.70M |
March 31, 2022 | 364.12M |
December 31, 2021 | 359.67M |
September 30, 2021 | 209.01M |
June 30, 2021 | 199.60M |
March 31, 2021 | 303.22M |
December 31, 2020 | 300.59M |
September 30, 2020 | 182.29M |
June 30, 2020 | 187.11M |
March 31, 2020 | 79.32M |
December 31, 2019 | 99.10M |
September 30, 2019 | 21.98M |
June 30, 2019 | 85.71M |
March 31, 2019 | 84.02M |
December 31, 2018 | 62.50M |
September 30, 2018 | 61.74M |
June 30, 2018 | 84.13M |
March 31, 2018 | 85.53M |
December 31, 2017 | 135.70M |
Date | Value |
---|---|
September 30, 2017 | 137.46M |
June 30, 2017 | 73.48M |
March 31, 2017 | 71.87M |
December 31, 2016 | 23.30M |
September 30, 2016 | 21.06M |
June 30, 2016 | -0.629M |
March 31, 2016 | 4.116M |
December 31, 2015 | 5.479M |
September 30, 2015 | 5.753M |
June 30, 2015 | 8.479M |
March 31, 2015 | 111.01M |
December 31, 2014 | 111.91M |
September 30, 2014 | 113.44M |
June 30, 2014 | 130.08M |
March 31, 2014 | 29.63M |
December 31, 2013 | 30.27M |
September 30, 2013 | 28.70M |
June 30, 2013 | 10.82M |
March 31, 2013 | 8.075M |
December 31, 2012 | 16.96M |
September 30, 2012 | 17.32M |
June 30, 2012 | 14.75M |
March 31, 2012 | 11.39M |
December 31, 2011 | 23.76M |
September 30, 2011 | 23.22M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
21.98M
Minimum
Sep 2019
431.25M
Maximum
Sep 2022
181.39M
Average
148.62M
Median
Cash from Financing (TTM) Benchmarks
AIM ImmunoTech Inc | 0.338M |
Perspective Therapeutics Inc | 0.461M |
Protalix BioTherapeutics Inc | 24.67M |
Electromed Inc | -0.128M |
Armata Pharmaceuticals Inc | 53.99M |